KAMADA LTD Share Price Today: Live Updates & Key Insights

KAMADA LTD share price today is $8.5, up -1.39%. The stock opened at $8.72 against the previous close of $8.62, with an intraday high of $8.72 and low of $8.445.

KAMADA LTD Share Price Chart

KAMADA LTD

us-stock
To Invest in {{usstockname}}
us-stock

KAMADA LTD Share Price Performance

$8.5 -0.0139(-1.39%) KMDA at 23 Mar 2026 01:52 PM Drug Manufacturers - Specialty & Generic
Lowest Today 8.445
Highest Today 8.72
Today’s Open 8.72
Prev. Close 8.62
52 Week High 9.35
52 Week Low 5.54
Day’s Range: Low 8.445 High 8.72
52-Week Range: Low 5.54 High 9.35
1 day return -
1 Week return -4.82
1 month return -4.28
3 month return +20.25
6 month return +22.51
1 year return +19.74
3 year return +94.27
5 year return +33.91
10 year return -

KAMADA LTD Institutional Holdings

ARK Israel Innovative Technology ETF 0.47

DFA International Small Company I 0.34

DFA International Core Equity 2 I 0.17

Dimensional International Sm Cp Val ETF 0.08

iShares Nasdaq US Biotech ETF USD Acc 0.07

Dimensional International Small Cap ETF 0.06

Fidelity Nasdaq Composite Index 0.05

Dimensional International Core Eq 2 ETF 0.05

Dimensional Global Trgtd Value USD Acc 0.05

Mandarine Global Microcap G EUR 0.04

Dimensional World ex US Core Eq 2 ETF 0.04

PGIM International Micro Cap Quant Eq 0.03

SEI World Equity Ex-US A (SIIT) 0.03

Metis International Micro Cap Equity 0.02

DFA International Vector Equity I 0.02

Gestión Boutique VIII River Global FI 0.02

DFA World ex US Core Equity Instl 0.02

Metis Global Micro Cap Equity 0.01

Brighthouse/Dimensional Intl Sm Cm A 0.01

DFA World ex US Targeted Val Instl 0.01

State of Tennessee, Treasury Department 0.00

KAMADA LTD Market Status

Strong Buy: 2

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

KAMADA LTD Fundamentals

Market Cap 491.44 M

PB Ratio 1.8223

PE Ratio 24.2857

Enterprise Value 435.66 M

Total Assets 378.79 M

Volume 134895

KAMADA LTD Company Financials

Annual Revenue FY23:151526000 151.5M, FY22:129339000 129.3M, FY21:103642000 103.6M, FY20:133246000 133.2M, FY19:127187000 127.2M

Annual Profit FY23:56369000 56.4M, FY22:46703000 46.7M, FY21:30328000 30.3M, FY20:47552000 47.6M, FY19:49737000 49.7M

Annual Net worth FY23:6170000 6.2M, FY22:-2321000 -2.3M, FY21:-2230000 -2.2M, FY20:17140000 17.1M, FY19:22251000 22.3M

Quarterly Revenue Q3/2025:47010000 47.0M, Q2/2025:44754000 44.8M, Q1/2025:44018000 44.0M, Q3/2024:41740000 41.7M, Q2/2024:41877208 41.9M

Quarterly Profit Q3/2025:19762000 19.8M, Q2/2025:18929000 18.9M, Q1/2025:20749000 20.7M, Q3/2024:17234000 17.2M, Q2/2024:18685604 18.7M

Quarterly Net worth Q3/2025:5296000 5.3M, Q2/2025:7376000 7.4M, Q1/2025:3964000 4.0M, Q3/2024:3863000 3.9M, Q2/2024:4426000 4.4M

About KAMADA LTD & investment objective

Company Information Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Organisation Drug Manufacturers - Specialty & Generic

Employees 462

Industry Drug Manufacturers - Specialty & Generic

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

KAMADA LTD FAQs

What is the share price of KAMADA LTD today?

The current share price of KAMADA LTD is $8.5.

Can I buy KAMADA LTD shares in India?

Yes, Indian investors can buy KAMADA LTD shares by opening an international trading and demat account with Motilal Oswal.

How to buy KAMADA LTD shares in India?

You can easily invest in KAMADA LTD shares from India by:

Can I buy fractional shares of KAMADA LTD?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of KAMADA LTD?

KAMADA LTD has a market cap of $491.44 M.

In which sector does KAMADA LTD belong?

KAMADA LTD operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in KAMADA LTD stocks?

To invest, you typically need:

What is the PE and PB ratio of KAMADA LTD?

The PE ratio of KAMADA LTD is 24.29 and the PB ratio is 1.82.